Clinical Trial

Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer

Study acronym: TREN
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Neoadjuvant chemotherapy is frequently proposed to patients with mammary gland cancer. The aim is to reduce tumor volume before surgical therapy. Obtaining a pathologic Complete Response (pCR) is regarded as a good prognostic factor with less risk of recurrence. The rate of pCR is about 20%, although there are important variations according to tumor subtype and the type of treatment. The objective of the new therapeutic strategies is to increase this response rate. The purpose of this study is to investigate the possibility of early evaluation of neoadjuvant chemotherapy response after one cycle of neoadjuvant chemotherapy by positron emission tomography (PET) with (18) F-fluorodeoxyglucose (FDG) in patients.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2015-03-11; most recent amendment 2024-02-12.
Status change: Recruiting → Active, Not Recruiting 2024-02-12
Status change: Not Yet Recruiting → Recruiting 2015-03-25
Trial Details
NCT Number NCT02386709
Lead Sponsor Centre Georges Francois Leclerc
Conditions FDG PET
Enrollment 275 participants
Start Date 2015-03-25
Primary Completion 2028-03-25 (estimated)
Study Completion 2028-03-25 (estimated)
Updated on ClinicalTrials.gov 2024-02-14